Patents Represented by Attorney, Agent or Law Firm Jennifer A. Kispert
  • Patent number: 8067594
    Abstract: The invention provides a process for producing a compound of formula (I), wherein Y is selected from the group consisting of CH3, CH2OH, CH2CH2OH, CH2Br and Br; comprising the steps of: (i) reacting a compound of formula (II), wherein OX represents hydroxy or O?M+, in which M+ is a cation selected from Li+, Na+ and K+, and Y is as defined above; with trans-cinnamaldehyde (III), in the presence of a secondary amine compound; then (ii) treating the product of the preceding step with acid to afford the compound of formula (I). The above process may also be used in the production of tolterodine and fesoterodine, which are useful in the treatment of overactive bladder.
    Type: Grant
    Filed: May 21, 2007
    Date of Patent: November 29, 2011
    Assignee: Pfizer Inc.
    Inventors: Jens Bertil Ahman, Barry Richard Dillon, Alan John Pettman
  • Patent number: 8067589
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment of various diseases and conditions such as asthma.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: November 29, 2011
    Assignee: Pfizer Inc
    Inventors: Tanisha D. Blake, Bruce C. Hamper, Wei Huang, James R. Kiefer, Jr., Joseph B. Moon, Bradley E. Neal, Kirk L. Olson, Matthew J. Pelc, Barbara A. Schweitzer, Atli Thorarensen, John I. Trujillo, Steven R. Turner
  • Patent number: 8063053
    Abstract: The invention relates to 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazole compounds of the Formula I: or a tautomer, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.
    Type: Grant
    Filed: November 11, 2009
    Date of Patent: November 22, 2011
    Assignee: Wyeth LLC
    Inventors: Simon Nicolas Haydar, Patrick Michael Andrae, Heedong Yun, Albert Jean Robichaud
  • Patent number: 8063044
    Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereofs, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
    Type: Grant
    Filed: August 25, 2008
    Date of Patent: November 22, 2011
    Assignee: Pfizer Inc.
    Inventors: Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
  • Patent number: 8044052
    Abstract: The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: October 25, 2011
    Assignee: Pfizer Inc.
    Inventors: Lorraine Kathleen Fay, Douglas S. Johnson, Suzanne Ross Kesten, Scott E. Lazerwith, Mark Anthony Morris, Cory Michael Stiff, Marvin Jay Meyers, Lijuan Jane Wang
  • Patent number: 8044227
    Abstract: Materials and methods for preparing (S)-(+)-3-aminomethyl-5-methyl-hexanoic acid and structurally related compounds via enzymatic kinetic resolution are disclosed.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: October 25, 2011
    Assignee: Pfizer Inc.
    Inventors: Shanghui Hu, Carlos Alberto Martinez, Junhua Tao, William Eugene Tully, Patrick Kelleher, Yves Dumond
  • Patent number: 8034960
    Abstract: The present invention provides a compound of formula 1: wherein R1 is CF3, R2 is H? R3 is H.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: October 11, 2011
    Assignee: Pfizer Inc.
    Inventors: Ronald S. Michalak, Mahmut Levent, Frederick J. Vyverberg, Ara R. Boyajian, Panolil Raveendranath, Michel Cantin, Alan Stockton, Michael W. Winkley, Mousumi Ghosh, Christoph Dehnhardt, Charles Guinosso
  • Patent number: 8022033
    Abstract: A complex of an echinocandin compound with a carbohydrate is described having improved thermal stability and water solubility. A process for making the echinocandin/carbohydrate complex is also described as well as the use of the complex in pharmaceutical formulations and treatments of fungal infections.
    Type: Grant
    Filed: May 21, 2009
    Date of Patent: September 20, 2011
    Assignee: Eli Lilly and Company
    Inventors: Larry Arnold Larew, Nathaniel Milton, James Lawrence Sabatowski, Kenneth Philip Moder
  • Patent number: 8013019
    Abstract: The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: September 6, 2011
    Assignee: Pfizer Inc
    Inventors: Alan Daniel Brown, Mark Edward Bunnage, Paul Alan Glossop, Kim James, Charlotte Alice Louise Lane, Russel Andrew Lewthwaite, Ian Brian Moses, David Anthony Price, Nicholas Murray Thomson
  • Patent number: 7977367
    Abstract: The present invention provides Formula (1A) compounds that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. X, Y, Z, R1, R2, R3, and R4 are as described herein.
    Type: Grant
    Filed: September 9, 2009
    Date of Patent: July 12, 2011
    Assignee: Pfizer Inc
    Inventors: John William Benbow, Jihong Lou, Jeffrey Allen Pfefferkorn, Meihua Mike Tu
  • Patent number: 7964607
    Abstract: The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: June 21, 2011
    Assignee: Pfizer Inc.
    Inventors: Patrick Robert Verhoest, Caroline Proulx-Lafrance
  • Patent number: 7964727
    Abstract: This invention provides a compound of the formula (I): wherein Het represents a heterocyclic group having one nitrogen atom, to which B binds directly, and from 4 to 7 carbon atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 4 substituents independently selected from the group consisting of substituents ?1; A represents an alkylene group having from 1 to 4 carbon atoms; B represents a covalent bond or an alkylene group having from 1 to 5 carbon atoms; R1 represents an isopropyl group, a n-propyl group or a cyclopentyl group; R2 represents a methyl group, a fluorine atom or a chlorine atom; R3 independently represents (i) an oxo group, a hydroxy group, an amino group, an alkylamino group or a carboxyl group; (ii) a cycloalkyl group having from 3 to 8 carbon atoms, and said cycloalkyl group being substituted by 1 to 5 substituents, or (iii) a heterocyclic group having from 3 to 8 atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 5 substituents, and n is 1,
    Type: Grant
    Filed: November 10, 2004
    Date of Patent: June 21, 2011
    Assignee: Pfizer Inc.
    Inventors: Tomoki Kato, Kiyoshi Kawamura, Mikio Morita, Chikara Uchida
  • Patent number: 7943628
    Abstract: A compound of Formula (I): or a pharmaceutically and/or veterinarily acceptable derivative thereof, wherein R1, R2, R3, R4, R5, and R8 are as defined above.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: May 17, 2011
    Assignee: Pfizer Limited
    Inventors: Andrew Simon Bell, Charlotte Alice Louise Lane, Charles Eric Mowbray
  • Patent number: 7939520
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: May 13, 2008
    Date of Patent: May 10, 2011
    Assignee: Wyeth LLC
    Inventors: Simon Nicolas Haydar, Patrick Andrae
  • Patent number: 7939675
    Abstract: A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: May 10, 2011
    Assignee: Pfizer, Inc.
    Inventors: Antone John deBettencourt, III, Evgenyi Yur'evich Shalaev
  • Patent number: 7935719
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor: wherein the variables are described in the specification.
    Type: Grant
    Filed: October 5, 2007
    Date of Patent: May 3, 2011
    Assignee: Wyeth LLC
    Inventors: William Ronald Solvibile, Ji-In Kim, Marla Jean Williams, Jonathan Laird Gross, Albert Jean Robichaud
  • Patent number: 7928099
    Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof wherein the variables R1, R2, R3a, R3b, R3b, R3d, and R100 are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a 5-HT2c receptor-mediated disorders with a compound of formula (I) or a pharmaceutical composition comprising a compound of formula (I).
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: April 19, 2011
    Assignee: Pfizer Inc
    Inventors: Mark Andrews, Julian Blagg, Paul Brennan, Paul Fish, R. Ian Storer, Gavin Whitlock
  • Patent number: 7919506
    Abstract: Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
    Type: Grant
    Filed: January 3, 2007
    Date of Patent: April 5, 2011
    Assignee: Pfizer Inc.
    Inventors: George Chang, Ravi S. Garigipati, Bruce Lefker, David A. Perry, Dongxiang Zeng
  • Patent number: 7919488
    Abstract: The present invention provides compounds of formula (I), or pharmaceutically acceptable salts or solvates thereof, methods for their preparation, methods for their use, and pharmaceutical formulations comprising them.
    Type: Grant
    Filed: June 28, 2007
    Date of Patent: April 5, 2011
    Assignee: Pfizer Inc.
    Inventors: Simon Paul Planken, Scott Channing Sutton, Rongliang Chen
  • Patent number: 7914820
    Abstract: The present invention relates to novel coating compositions for application to solid dosage forms such as tablets or caplets, solid dosage forms coated with the composition, and methods of preparing said coating compositions.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: March 29, 2011
    Assignee: Warner-Lambert Company LLC
    Inventors: Robert Anthony Scott, Dominique Cade, Frederic Hoehn, Ewart Thomas Cole